6 Large-Cap Stocks Outperforming the Benchmark

Disney tops the list

Author's Avatar
Jun 12, 2019
Article's Main Image

According to the GuruFocus All-in-One Screener, the following stocks have outperformed the Standard & Poor's 500 Index over the last 12 months.

The Walt Disney Co. (DIS, Financial) has a market cap of $248.43 billion. It has outperformed the S&P 500 by 32.69% over the past year.

173799538.png

Shares are trading with a price-earnings ratio of 15.52. According to the discounted cash flow calculator, the stock is undervalued with a 27% margin of safety at $136. The price is currently 38.52% above its 52-week low and 2.36% below its 52-week high.

The entertainment company has a profitability and growth rating of 8 out of 10. The return on equity of 24.05% and return on assets of 11.05% are outperforming 87% of companies in the Media - Diversified industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.18 is below the industry median of 0.82.

Yacktman Asset Management (Trades, Portfolio) is the company's largest guru shareholder with 0.25% of outstanding shares, followed by Pioneer Investments (Trades, Portfolio) with 0.20% and PRIMECAP Management (Trades, Portfolio) with 0.18%.

With a market cap of $239.42 billion, Cisco Systems Inc. (CSCO, Financial) has outperformed the S&P 500 by 27.50% over the last 12 months.

1177487209.png

Shares are trading with a price-earnings ratio of 19.29. According to the DCF calculator, the stock is overpriced by 80% at $56 per share. The price is currently 39.20% above its 52-week low and 2.60% below its 52-week high.

The data networking equipment and software provider has a profitability and growth rating of 8 out of 10. The return on equity of 31.28% and return on assets of 12.52% are underperforming 69% of companies in the Communication Equipment industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 1.46 is below the industry median of 2.

The company’s largest guru shareholder is Dodge & Cox with 0.71% of outstanding shares, followed by Ken Fisher (Trades, Portfolio) with 0.65%, PRIMECAP Management with 0.46% and Tweedy Browne (Trades, Portfolio) with 0.18%.

Pfizer Inc. (PFE, Financial) has a market cap of $238.63 billion. It has outperformed the S&P 500 by 17.76% over the past year.

2041665165.png

Shares are trading with a price-earnings ratio of 22. According to the DCF calculator, the stock is overpriced by 83% at $43. The price is currently 20.35% above its 52-week low and 7.47% below its 52-week high.

The pharmaceutical company has a profitability and growth rating of 8 out of 10. The return on equity of 17.20% and return on assets of 7.06% are outperforming 87% of companies in the Drug Manufacturers - Major industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.26 is below the industry median of 2.03.

The company’s largest guru shareholder is Fisher with 0.77% of outstanding shares, followed by Barrow, Hanley, Mewhinney & Strauss with 0.37%, Pioneer Investments with 0.22% and the T Rowe Price Equity Income Fund (Trades, Portfolio) with 0.17%.

With a market cap of $236.73 billion, Verizon Communications Inc. (VZ, Financial) has outperformed the S&P 500 by 17.93% over the last 12 months.

561655860.png

Shares are trading with a price-earnings ratio of 14.75. According to the DCF calculator, the stock is overpriced by 37% at $57.24 per share. The price is currently 21.79% above its 52-week low and 6.79% below its 52-week high.

The company, which provides wireless and wireline services, has a profitability and growth rating of 5 out of 10. The return on equity of 30.07% and return on assets of 5.97% are outperforming 90% of companies in the Telecom Services industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.02 is below the industry median of 0.3.

Barrow, Hanley, Mewhinney & Strauss is the company's largest guru shareholder with 0.20% of outstanding shares, followed by the T Rowe Price Equity Income Fund with 0.17%, Pioneer Investments with 0.15% and John Rogers (Trades, Portfolio) with 0.03%.

Merck & Co. Inc. (MRK, Financial) has outperformed the S&P 500 by 32.64% over the past year. The company has a market cap of $212.31 billion.

1392382902.png

Shares are trading with a price-earnings ratio of 26. According to the DCF calculator, the stock is undervalued with a 143% margin of safety at $82.46 per share. As of Wednesday, the price was 37.89% above its 52-week low and 1.66% below its 52-week high.

The pharmaceutical company has a profitability and growth rating of 7 out of 10. The return on equity of 27.47% and return on assets of 9.97% are underperforming 56% of companies in the Drug Manufacturers - Major industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.34 is below the industry median of 2.03.

The company’s largest guru shareholder is the Vanguard Health Care Fund (Trades, Portfolio) with 0.70% of outstanding shares, followed by Fisher with 0.33%, Pioneer Investments with 0.30% and PRIMECAP Management with 0.13%.

Novartis AG (NVS, Financial) has a market cap of $202.01 billion. It has outperformed the S&P 500 by 33.45% over the last 12 months.

1374515823.png

Shares are trading with a price-earnings ratio of 16.82. According to the DCF calculator, the stock is overpriced by 54% at $88.06 per share. The price is currently 38.47% above its 52-week low and 0.62% below its 52-week high.

The pharmaceutical company has a profitability and growth rating of 8 out of 10. The return on equity of 17.75% and return on assets of 8.85% are outperforming 80% of companies in the Drug Manufacturers - Major industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.25 is below the industry median of 2.03.

The company’s largest guru shareholder is Dodge & Cox with 1.56% of outstanding shares, followed by PRIMECAP Management with 1.03%, Fisher with 0.34% and Jim Simons (Trades, Portfolio)’ Renaissance Technologies with 0.14%.

Disclosure: I do not own any of the stocks mentioned.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.